Physician profile
Brandy Mcgraw
NPI 1972015501
$14,289.40
in general payments reported to CMS, 2019-2025
29 companies · $2,746 in 2025
The $2,746 reported for 2025 was more than what 98% of Primary Care providers received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,285 · 2022: $2,452 · 2023: $3,104 · 2024: $3,703 · 2025: $2,746.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,433 · Education: $120.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,432.64 |
| Education | $119.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $4,426.67 | 2021-2025 | |
| Amgen INC. | $3,303.44 | 2021-2025 | Enbrel, Evenity, Otezla |
| Janssen Biotech, INC. | $1,545.38 | 2021-2025 | Tremfya, Simponi Aria |
| Novartis Pharmaceuticals Corporation | $1,134.95 | 2021-2025 | |
| Ucb, INC. | $590.26 | 2021-2025 | Bimzelx, Cimzia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $581.43 | 2021-2025 | Ofev, Cyltezo |
| Glaxosmithkline, LLC. | $518.88 | 2023-2025 | Benlysta |
| Radius Health, INC. | $369.35 | 2021-2025 | Tymlos |
| Lilly USA, LLC | $362.85 | 2021-2024 | Taltz |
| Janssen Scientific Affairs, LLC | $253.25 | 2023-2025 | Tremfya |
| Pfizer INC. | $237.02 | 2021-2025 | |
| Aurinia Pharma U.S., INC. | $172.46 | 2021-2025 | Lupkynis |
| Horizon Therapeutics Plc | $124.99 | 2023 | Krystexxa |
| Astrazeneca Pharmaceuticals LP | $117.21 | 2024-2025 | Saphnelo |
| Mallinckrodt Hospital Products INC. | $65.33 | 2025 | Acthar |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $62.26 | 2023-2024 | Opsumit |
| Organon LLC | $62.17 | 2023-2025 | Hadlima |
| Alexion Pharmaceuticals, INC. | $51.10 | 2025 | Strensiq |
| Kiniksa Pharmaceuticals International, Plc | $49.74 | 2024 | Arcalyst |
| Genentech USA, INC. | $36.50 | 2023-2024 | Actemra |
| E.R. Squibb & Sons, L.L.C. | $36.29 | 2025 | Orencia |
| Sandoz INC. | $34.80 | 2023-2024 | Hyrimoz |
| Ani Pharmaceuticals, INC. | $33.77 | 2024 | Purified Cortrophin Gel |
| Sobi, INC | $31.82 | 2022 | |
| Kiniksa Pharmaceuticals, LTD. | $20.01 | 2023 | Arcalyst |
| Cumberland Pharmaceuticals, INC. | $18.09 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $18.04 | 2023 | Trintellix |
| Corcept Therapeutics | $17.91 | 2022 | |
| Fresenius Kabi USA, LLC | $13.43 | 2024 | Idacio |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brandy Mcgraw listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.